Supreme Court declines drugmaker appeals against Medicare drug price negotiation program

By ··2 min read

The US Supreme Court rejected appeals from pharmaceutical companies challenging the Medicare drug price negotiation program created by the 2022 Inflation Reduction Act. The justices left in place Third Circuit rulings dismissing the manufacturers' claims without comment.

The US Supreme Court on May 18, 2026, declined to hear appeals from pharmaceutical manufacturers challenging the Medicare drug price negotiation program, leaving in place rulings from the US Court of Appeals for the Third Circuit in Philadelphia that had dismissed the companies' claims. The justices issued no comment.

The program was created by the Inflation Reduction Act of 2022, which ended a prohibition on direct federal negotiation of drug prices in Medicare Part D. The law requires the Secretary of Health and Human Services to negotiate prices each year for certain high-cost, single-source drugs, and imposes an excise tax on manufacturers that decline to participate. Drugmakers have challenged the scheme since June 2023 on First and Fifth Amendment grounds and on statutory grounds, and have lost repeatedly in the lower courts. Negotiated prices for the first ten drugs took effect on January 1, 2026. Prices for a second group of 15 drugs, including Ozempic, Rybelsus and Wegovy, take effect on January 1, 2027.

The pharmaceutical industry has argued that policymakers seeking lower costs should focus on insurers and pharmacy benefit managers rather than manufacturers. Patient advocates welcomed the decision; Merith Basey, chief executive of Patients For Affordable Drugs, said attention should now shift to full implementation and expansion of the program.

The refusal to hear the cases removes the most direct route for industry to overturn the program in court. The Trump administration has continued to defend the program in litigation. Congress has separately moved to limit the program's scope. For hospitals, pharmacies and plan sponsors, the decision gives greater certainty that negotiated maximum fair prices will continue to be phased in.

The third negotiation cycle is under way. CMS was due to send initial offers by June 1, with final agreements due by November 1, and resulting prices will be published by November 30 and take effect January 1, 2028. Other manufacturer challenges remain active, including cases brought by AbbVie and PhRMA.

Cite this report

The Precedent. "Supreme Court declines drugmaker appeals against Medicare drug price negotiation program." September 5, 2026. https://theprecedent.org/article/supreme-court-declines-drugmaker-appeals-against-medicare-drug-price-negotiation

Companies in this report